Clinical trials: CtDNA
Colorectal Cancer, Rectal Cancer
Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer
The purpose of this study is to use the SignateraTm assay created from rectal tumor biopsies to monitor participants' blood for fragments of DNA shed by tumor cells.
- Trial name
- NCT05356585
- Testing
- SignateraTM assay
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Melanoma
Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma
This study aims at assessing the role of MerlinTM and ctDNA in predicting the nodal status in patients with >pT3b melanoma, therefore candidate for adjuvant therapy regardless of sentinel lymph node status.
- Trial name
- CORRESPOND (NCT06566404)
- Volunteers
- 200 people
- Sponsor
- European Institute of Oncology
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNADalHR (NCT06970912)
- Testing
- Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Peking University People's Hospital
Metastatic Colorectal Cancer, Pancreas Adenocarcinoma
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
Circulating tumor DNA assays are becoming relevant for routine diagnostics, but many related aspects are yet unresolved. With this project, the investigators aim to develop pragmatic molecular diagnostic pathways of liquid…
- Conditions
- Metastatic Colorectal Cancer, Pancreas Adenocarcinoma, Cholangiocarcinoma
- Trial name
- NCT06290856
- Testing
- Multiplex PCR-test for circulating tumor DNA
- Where
- Norway
- Volunteers
- 16 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer Metastatic, Circulating Tumor DNA
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.
- Conditions
- Colorectal Cancer Metastatic, Circulating Tumor DNA, KRAS Gene Mutation, NRAS Gene Mutation
- Trial name
- OPTIPAL-II (NCT03750175)
- Testing
- Plasma circulating DNA analysis
- Where
- Denmark
- Volunteers
- 49 people
- Sponsor
- Karen-Lise Garm Spindler
Breast Cancer
Liquid Biopsies and Imaging in Breast Cancer
The aim of the study is to show proof of concept for combining multi-parametric MRI with liquid biopsies in addition to conventional clinical and pathologic information, to accurately predict response to neoadjuvant treatment for…
- Trial name
- LIMA (NCT04223492)
- Testing
- Liquid biopsy, Multi-parametric MRI
- Where
- Netherlands
- Volunteers
- 61 people
- Sponsor
- UMC Utrecht
Lung Cancer, Non-small Cell, EGFR Gene Mutation
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%.
- Conditions
- Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation, Primary Resistance
- Trial name
- PRECISE (NCT05598528)
- Testing
- Genomic profiles detection, circulating tumor DNA detection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Second Xiangya Hospital of Central South University
Thyroid Cancer, Thyroid Nodules
ctDNA in Patients With Thyroid Nodules
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream.
- Conditions
- Thyroid Cancer, Thyroid Nodules, Thyroid Adenoma, Thyroiditis
- Trial name
- NCT02778412
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Pathway Genomics
Colorectal Cancer
Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence
This observational study aims to assess the predictive value of postoperative circulating tumor DNA (ctDNA) monitoring in evaluating the risk of recurrence in stage I-IV colorectal cancer patients.
- Trial name
- NCT06143644
- Testing
- Serial ctDNA monitoring
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery.
- Trial name
- DNA-PREDICT (NCT06902272)
- Testing
- Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02245100
- Testing
- Cytology specimen, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
HPV Positive Pelvic Cancer
Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses (CIRCA-HPV)
ctDNA detection in patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up.
- Trial name
- CIRCA-HPV (NCT03739775)
- Testing
- Blood sampling
- Where
- 5 sites in France
- Volunteers
- 172 people
- Sponsor
- Institut Curie
Colon Cancer, Colon Adenomas
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream.
- Conditions
- Colon Cancer, Colon Adenomas, Colon Polyps
- Trial name
- NCT02665299
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Pathway Genomics
Colon Cancer, Deficient Mismatch Repair
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This prospective, multicenter, single-arm phase II interventional study evaluates whether longitudinal circulating tumor DNA (ctDNA) monitoring can guide neoadjuvant immunotherapy and surgical decision-making in dMMR/MSI-H colon…
- Conditions
- Colon Cancer, Deficient Mismatch Repair, Microsatellite Instability-High (MSI-H)
- Trial name
- NCT07841236
- Testing
- PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Fudan University
Colorectal Tumor
Comparison of Diagnostic Sensitivity Between ctDNA Methylation and CEA in Colorectal Cancer
This is a prospective diagnostic study. This study is to compare the performance between circulating tumor DNA (ctDNA) methylation and carcinoembryonic antigen (CEA) in detecting colorectal tumor.
- Trial name
- NCT05558436
- Testing
- Genome-wide methylation profiling
- Where
- China
- Volunteers
- 662 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Metastatic Breast Cancer (HR+/ HER2-)
Predicting Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer
This prospective observational study aims to evaluate the prognostic value of molecular imaging biomarkers derived from baseline [18F]FES and [18F]FDG PET/CT for progression-free survival in patients with estrogen receptor…
- Trial name
- NCT07867925
- Testing
- [18F] FES
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Breast Cancer
ctDNA in HER2+ EBC Neoadjuvant Treatment
This study is a randomized, open-label, multicenter clinical study for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer, aiming to compare the peripheral blood ctDNA clearance of neoadjuvant…
- Trial name
- NCT07335081
- Testing
- pyrotinib, pertuzumab, trastuzumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Colorectal Cancer, Melanoma
BESPOKE Study of ctDNA Guided Immunotherapy
This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing.
- Conditions
- Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer
- Trial name
- NCT04761783
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Natera, Inc.
Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases.
- Conditions
- Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia, Systemic Chronic Active Epstein-Barr Virus Disease, Epstein-Barr Virus-Positive Nodal T/NK-Cell Lymphoma
- Trial name
- EBV-T/NK Cohor (NCT07727083)
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Rong Tao
Leptomeningeal Metastasis
Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
The purpose of this study is to learn whether the DNA from cancer tumor cells can be found in the cerebral spinal fluid (CSF) that bathes the brain and spinal cord of patients before malignant the cancer cells themselves are able…
- Trial name
- NCT02071056
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dartmouth-Hitchcock Medical Center